Insight Molecular Diagnostics Inc (OCX)

Currency in USD
2.01
0.00(0.00%)
Closed·
Showing Insight Molecular Diagnostics historical data. For real-time data please try another search
Day's Range
2.012.12
52 wk Range
0.002.12
Key Statistics
Prev. Close
1.95
Open
2.06
Day's Range
2.01-2.12
52 wk Range
0-0
Volume
-
Average Volume (3m)
0
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Insight Molecular Diagnostics Inc Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Industry
Biotechnology & Medical Research
Sector
-

Insight Molecular Diagnostics Inc Earnings Call Summary for Q2/2025

  • Q2 laboratory services revenue at $494,000, slightly below $500,000 target; gross margins nearly 68%
  • Launched second-generation GraftAssure IQ kits; preparing FDA submission for kidney transplant rejection test by end of 2025
  • Cash position at $26 million; quarterly burn rate of $6.3 million plus $350,000 in capital expenditures
  • Anticipates FDA approval between Q2-Q3 2026; plans commercial launch mid-2026 with $6 million average quarterly cash burn
  • Exploring expansion into heart, lung, and liver transplant indications to diversify market presence
Last Updated: 11/08/2025, 23:24
Read Full Transcript

Earnings

Latest Release
Nov 12, 2019
EPS / Forecast
-- / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

OCX Income Statement

People Also Watch

3.040
MBOT
-2.56%
0.400
ADIL
+1.27%
1.990
IPA
-1.49%
2.450
CRDF
+0.82%
4.050
ATAI
-1.94%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.